TCR2 Therapeutics Inc. (TCRR)
1.48
0.00 (0.00%)
At close: May 31, 2023, 8:00 PM
0.00% (1D)
| Bid | n/a |
| Market Cap | 58.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -163.1M |
| EPS (ttm) | -4.2 |
| PE Ratio (ttm) | -0.3523809523809524 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 3,753,354 |
| Avg. Volume (20D) | 325,040 |
| Open | 1.58 |
| Previous Close | 1.48 |
| Day's Range | 1.48 - 1.48 |
| 52-Week Range | 0.82 - 3.88 |
| Beta | 1.93 |
About TCRR
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 14, 2019
Employees 58
Stock Exchange NASDAQ
Ticker Symbol TCRR
Website https://www.tcr2.com